[DK통신] “옵디보여보이 PFS 대조군 대비 통계적유의성 확보 실패
9.1개월 vs 대조군 9.2개월(LEN/SOR), HR=0.87로 미 FDA 기준 미 충족
리보캄렐 간암 1차 적수가 완전히 전무해진 상황
PFS가 임상 목표에 없다고? 이때 이미 알고 있었지만, 옵디보여보이는 이제 안녕, 리보캄렐 PFS HR=0.54로 46% 개선
he primary endpoint was overall survival (OS). Secondary endpoints included objective response rate (ORR) and duration of response (DOR) per blinded independent central review (BICR) using RECIST v1.1.
"What this study does primarily is give us 3 options to think about in the first-line setting that have all beaten the previous standard.”
Median progression-free survival was similar between the arms at 9.1 months with nivolumab plus ipilimumab compared with 9.2 months with lenvatinib or sorafenib. However, the progression-free survival rates were higher with the combination at 18 months (34% vs 18%) and 24 months (28% vs 12%).